Background and purpose: Brain atrophy is related to clinical deterioration in multiple sclerosis (MS) but its association with intrathecal markers of inflammation or neurodegeneration is unclear. Our aim was to investigate whether cerebrospinal fluid (CSF) markers of inflammation or neurodegeneration are associated with brain volume change in natalizumab-treated MS and whether this change is reflected in non-lesional white matter metabolites. Methods: About 25 patients with natalizumab-treated MS were followed for 3 years with assessment of percentage brain volume change (PBVC) and absolute quantification of metabolites with proton magnetic resonance spectroscopy ( 1 H MRS). Analyses of inflammatory [interleukin 1b (IL-1b), IL-6, C-X-C motif chemokine 8 (CXCL8), CXCL10, CXCL11, C-C motif chemokine 22] and neurodegenerative [neurofilament light protein (NFL), glial fibrillary acidic protein, myelin basic protein, tau proteins] markers were done at baseline and 1-year follow-up. Results: The mean decline in PBVC was 3% at the 3-year follow-up, although mean 1 H MRS metabolite levels in non-lesional white matter were unchanged. CSF levels of NFL and tau at baseline correlated negatively with PBVC over 3 years (r = À0.564, P = 0.012, and r = À0.592, P = 0.010, respectively). Conclusions: A significant 3-year whole-brain atrophy was not reflected in mean metabolite change of non-lesional white matter. In addition, our results suggest that CSF levels of NFL and tau correlate with brain atrophy development and may be used for evaluating treatment response in inflammatory active MS.
Introduction
Irreversible neuroaxonal damage is well established to constitute the pathological basis for progressive neurological decline in multiple sclerosis (MS) [1] . The accumulation of neuroaxonal damage relates to brain atrophy development, and measures of brain volume loss, as a proxy for brain atrophy, thus appear a promising method to assess risk for clinical deterioration and evaluate treatment response in MS [2, 3] . However, there are aspects to be considered if measures of brain volume are used for disease monitoring. First, a decline in brain volume is an end-stage phenomenon only to be detected retrospectively [4] . Biomarkers that may predict such future atrophy development are therefore needed to make early intervention possible. Secondly, loss of brain volume due to the resolution of inflammatory oedema during treatment, i.e. pseudoatrophy, may aggravate the interpretation of true coincident neuroaxonal loss [5] . In this perspective, magnetic resonance spectroscopy ( 1 H MRS) complements brain volume measurements regarding ongoing pathological processes in vivo.
In this longitudinal study, 25 patients with natalizumab-treated MS were followed for 3 years with magnetic resonance imaging (MRI) including 1 H MRS metabolite concentrations in normal appearing white matter (NAWM) and measurements of percentage brain volume change (PBVC). The main aim was to investigate if intrathecal markers of neurodegeneration or inflammation were associated with change in brain volume. As a complement to the evaluation of brain volume change, our aim was also to study NAWM 1 H MRS spectra investigating possible reflections of brain volume loss at the metabolite level.
Methods

Patients
Natalizumab treatment (300 mg intravenously once a month) was initiated in 25 patients with relapsing MS according to general guidelines based on clinical and MRI parameters ( Table 1 ). The study was observational and set up in a clinical setting and for ethical reasons there was no placebo-treated group. All included patients fulfilled the McDonald criteria for MS [6] and were consecutively recruited from the Department of Neurology at the University Hospital, Link€ oping. MRI examinations were performed before starting treatment [mean 1.6 AE 2.0 (SD) months], i.e. baseline, after 1 year of treatment [mean 12.6 AE 1.1 (SD) months] and after 3 years of treatment [mean 37.2 AE 1.2 (SD) months]. Eleven patients experienced a relapse within 3 months prior to baseline MRI. The 3-year follow-up MRI was done at least 3 months after the latest relapse. Cerebrospinal fluid (CSF) sampling was obtained before the start of natalizumab treatment [mean 1.6 AE 2.5 (SD) months] and after 1 year of treatment [mean 12.4 AE 1.4 (SD) months]. Neurological examination was done by a neurologist (MV, CD or JM) including definition of the Expanded Disability Status Scale (EDSS) at baseline and at 1-and 3-year follow-up. For the patient cohort in this study the effects of 1-year natalizumab treatment on CSF cytokine and chemokine levels (nine patients) [7] and on CSF levels of neurodegenerative markers (20 patients) [8] have been published before. Baseline and 1-year follow-up data on 1 H MRS and clinical scoring after natalizumab treatment (23 patients) have also been published previously [8] . The study was approved by the Regional Ethics Committee in Link€ oping (D no. M180-07 T130-09) and written consent was obtained from participants.
Cerebrospinal fluid biomarkers
Handling of CSF and assessment of cytokine concentrations using a multiple bead kit (InvitrogenÒ Cytokine Ultrasensitive Human 10-plex Panel, Carlsbad, CA, USA) was done as previously described [7] . An in-house assay was used to measure concentrations of C-X-C motif chemokine 10 (CXCL10), CXCL11 and C-C motif chemokine 22 (CCL22) [7] . The samples were analysed on a Luminex 100 instrument (Biosource, CA, USA), and data were acquired using StarStation 2.0 software (Applied Cytometry Systems, Sheffield, UK). Cytokine and chemokine values under the detection limit were assigned to half the value of the lowest standard point. CSF myelin basic protein was analysed using a sandwich enzyme-linked immunosorbent assay (ELISA) (Active MBP ELISA; Diagnostic Systems Laboratories Inc., Webster, TX, USA). The lower limit of detection for this assay was 0.1 ng/ml. CSF total tau (tau) and tau phosphorylated at threonine 181 (P-tau) were determined using the Luminex xMAP technology and the INNOBIA AlzBio3 kit (Innogenetics, Zwijndrecht, Belgium) as previously described [9] . CSF neurofilament light protein (NFL) and glial fibrillary acidic protein were analysed using previously described ELISAs [10, 11] .
Magnetic resonance imaging data acquisition
All examinations were performed using an Achieva 1.5 T MR scanner (Philips, Best, The Netherlands) and an eight-channel SENSE head coil. A standard MRI protocol with T 2 weighted (T2W) and T 1 weighted (T1W) sequences including pre-and postgadolinium (GD) and fluid attenuation inversion recovery (FLAIR) images was used for clinical radiological evaluation by a neuroradiologist (IB). Acquisition of R 1 , R 2 (1/T 2 ), PD and placement of 1 H MRS voxels was done as previously described [8] (Fig. 1) . In the initial phase of the project (for the first 24 patients at baseline, and the first nine patients at the 1-year follow-up) a single MRS voxel was acquired. In a later phase of the project (for the last three patients at baseline, the last 18 patients at the 1-year follow-up and for all 25 patients at 3-year follow-up), the examination time allowed for a second MRS voxel, which was added and placed using the same criteria but lateral and opposite to the first MRS voxel.
Absolute quantification of MRS data
The MRS spectra were analysed using LCModel version 6.2-4G (S. Provencher, Canada) [12] , with a spectral basis set obtained from Dr M. Ljungberg at Sahlgrenska Academy (Gothenburg, Sweden). Absolute aqueous fraction concentrations (mM aq) were estimated using the method described previously [13] .The internal water signal was used as an internal reference. The metabolites total creatine, total choline, myo-inositol (mIns), total N-acetylaspartate (tNA) and the sum of glutamate and glutamine were analysed [14] (Fig. 1) . In order to avoid bias towards high concentrations, no measurements were excluded from the subsequent statistical analysis based on the CramerÀRao low bounds estimation in the LCModel analysis [15] . The spectra were visually inspected for improper residuals and large artefacts in the spectral region of interest (4.0-0.2 ppm). However, no spectra were excluded due to such residuals or artefacts.
Calculation of percentage brain volume change
Percentage brain volume change calculations were based on segmentation of the axial FLAIR volume.
First, a registration of the FLAIR volumes for the different time points was carried out, using Analyze version 10 (Analyzedirect, Overland Park, KS, USA). The Analyze software was also used to cut border slices that differed after the registration. Secondly, the parenchymal tissue and lateral ventricles were segmented using the Image Foresting Transform [16] . Thirdly, the parenchymal volume was calculated as the subtraction between segmented brain volume including ventricles minus segmented ventricular volume. To calculate PBVC, the difference between parenchymal volumes at time points was normalized to baseline parenchymal volumes.
Statistics
Pairwise comparisons of clinical scoring variables were analysed using the Wilcoxon signed rank test. Pairwise comparisons of 1 H MRS metabolites and the MRI variable R 2 were analysed using the paired samples t test. Differences in PBVC (baseline compared with 1-and 3-year follow-up) were calculated using the one sample t test. Differences in PBVC at 1-and 3-year follow-up between patients with or without gadolinium enhanced (GD+) lesions at baseline MRI were analysed using the unpaired samples t test. Correlation analyses between intrathecal markers and change in 1 H MRS metabolites or PBVC were performed using the Spearman correlation coefficient. A possible association between age and levels of NFL, tau or PBVC was investigated using Spearman or Pearson correlation coefficients, respectively. Correlation analyses between PBVC and ratios of 1 H MRS metabolites were done using the Pearson correlation coefficient. Significance values for correlation coefficients are reported without correction for multiple comparisons to avoid type II errors [17] . All statistical calculations were performed in Statistica 12 software (Statsoft Inc., OK, USA) or Graphpad Prism 5 (GraphPad Software Inc., CA, USA). P < 0.05 was considered statistically significant.
Results
Clinical data
During the 3-year follow-up time there were in total 12 relapses amongst six patients (Table 2) . Steroid treatment (oral) was given only to the patient who had in total five relapses (at every relapse). At 1-year follow-up only one patient had a relapse within 6 months prior to the follow-up sample. The mean annual relapse rate during the whole 3-year follow-up period was 0.15 (12 relapses/77.5 person-years). There Figure 1 In the left column typical proton magnetic resonance spectroscopy ( 1 H MRS) voxel of interest placements are shown on a sagittal FLAIR image, for baseline, 1-year follow-up and 3-year follow-up. In the right column corresponding spectra are presented. mIns, myo-inositol; tCho, total choline; tCr, total creatine; Glx, the sum of glutamate and glutamine; NAAG, N-acetylaspartylglutamate; NAA, N-acetylaspartate. The sum of NAAG and NAA constitute tNA, total N-acetylaspartate. [Color figure can be viewed at wileyonlinelibrary.com].
was an improvement in clinical scoring variables during the follow-up time and EDSS remained unchanged (Table 2) .
Magnetic resonance spectroscopy metabolite concentrations
Mean
1 H MRS metabolite concentrations were stable during the whole 3-year follow-up period (Table 3) . Since the ratio between mIns and tNA in NAWM has been proposed as a predictive measure of brain volume loss [18] , ratios of these metabolites at baseline, 1-and 3-year follow-up were calculated. No difference in the ratios was found, however (data not shown). mIns/tNA ratios were then tested for correlations versus PBVC from baseline to 1-and 3-year follow-up, respectively. No correlations were found (data not shown). The free water content in examined voxels, represented by R 2 , did not change from baseline to 1-or 3-year follow-up (data not shown). Data on 1 H MRS metabolite concentrations at baseline and 1-year follow-up have previously been published for this patient cohort [8] . In order to evaluate our previous findings in this cohort, i.e. an association between 1-year change in 1 H MRS metabolites and levels of markers of intrathecal inflammation [8] tNA, total N-acetylaspartate; tCr, total creatine; tCho, total choline; mIns, myo-inositol; tGlx, the sum of glutamate and glutamine; R 2 , MRI variable 1/T 2 . Three-year mean difference in metabolite concentrations are presented with a 95% confidence interval (CI) and P values were calculated using the paired samples t test. All concentration values are presented in units of mM aq. Table 3 Proton magnetic resonance spectroscopy metabolite levels and magnetic resonance imaging (MRI) variable R 2 at baseline and after 1 and 3 years of natalizumab treatment correlation analyses were extended to the total followup period of 3 years. However, no correlation between levels of cytokines or chemokines after 1 year of natalizumab treatment and change in 1 H MRS metabolite concentrations between 1 and 3 years of treatment was found (data not shown).
Magnetic resonance imaging data and PBVC
In 23 of 25 patients data were available on GD+ lesions at baseline. Seven of these 23 patients (30%) showed GD+ lesions at baseline. At 1 and 3 years of treatment no patient showed GD+ lesions (data on 25 patients were available for both occasions). Five patients (20%) showed either at least one newly appearing lesion or at least one enlarged lesion on T2W at 1-year follow-up. At 3-year follow-up, six patients (24%) showed either at least one new or enlarged lesion on T2W. There was a significant brain volume loss as measured by a decrease in PBVC between baseline and 3-year follow-up [mean 97.0% AE 2.1% (SD); thus a mean difference in PBVC compared with baseline of À3.0%, P < 0.0001, Fig. 2a ]. There was also a significant decrease in PBVC already at 1-year follow-up compared with baseline [mean 98.2% AE 1.6% (SD); thus a mean difference in PBVC compared with baseline of À1.8%, P < 0.0001, Fig. 2a] . When excluding patients with relapses during follow-up, similar findings were obtained: the mean PBVC from baseline to 1 year changed to 98.1% (excluding two patients) and from baseline to 3-year follow-up it changed to 96.7% (excluding six patients). There was no difference in PBVC during follow-up comparing patients with or without new or enlarged lesions on T2W.
Based on the presence of GD+ lesions at baseline, the evolution of PBVC from baseline to 3-year followup was then studied. No statistically significant differences in PBVC at 1-or 3-year follow-up according to the presence or absence of GD+ lesions at baseline were found, however, although patients with GD+ lesions at baseline tended to decrease more in PBVC than patients with no baseline GD+ lesions (P = 0.078, Fig. 2b ). 
Percentage brain volume change and intrathecal markers of inflammation and neurodegeneration
Correlation analyses showed that NFL at baseline correlated with PBVC during the 3-year follow-up period (r = À0.564, P = 0.012, Fig. 2c) . Furthermore, NFL levels at 1-year follow-up and PBVC the following 2 years tended to correlate (r = À0.409, P = 0.073, n = 20). Levels of tau at baseline correlated with PBVC at 3-year follow-up (r = À0.592, P = 0.010, Fig. 2d ) and 1-year follow-up (r = À0.607, P = 0.008, n = 18). Excluding patients with relapses during follow-up yielded similar results in the correlation analyses as in the whole patient group. As to baseline NFL and PBVC during the 3-year follow-up (excluding three patients), there was a tendency to a correlation (r = À0.492, P = 0.053, n = 16). For baseline tau, the same analysis (excluding four patients) showed a correlation versus PBVC over 3 years (r = À0.634, P = 0.015, n = 14). There was no correlation between age on one hand and NFL, tau or PVBC on the other hand (data not shown). Levels of CXCL11 at 1-year follow-up correlated with PBVC the following 2 years (r = À0.4502, P = 0.046, n = 20). No other significant correlations between CSF levels of markers of inflammation [interleukin 1b (IL-1b), IL-6, CXCL8, CXCL10, CXCL11, CCL22] or neurodegeneration (glial fibrillary acidic protein, myelin basic protein, tau, P-tau) at baseline or 1-year follow-up versus corresponding PBVC at 1-or 3-year follow-up were found (data not shown).
Percentage brain volume change and change in 1 H
MRS metabolites
Percentage brain volume change from baseline to 1-and 3-year follow-up correlated with change in tNA concentration during the same time period (r = À0.403, P = 0.046, and r = À0.522, P = 0.008, respectively, Table 4 ). There was also a correlation between PBVC from 1-to 3-year follow-up versus change in the MRI variable R 2 (r = 0.518, P = 0.008, Table 4 ) as well as a tendency for a correlation between PBVC and change in R 2 over 3 years (r = 0.375, P = 0.065, Table 4 ). No other correlations between changes in 1 H MRS metabolite concentrations and corresponding PBVC were found (Table 4) .
Discussion
This paper is the first to report a 3-year longitudinal study on brain volume change in MS and its association with markers of neurodegeneration and inflammation as well as NAWM metabolite levels.
Assessment of metabolite concentrations in NAWM was used as a complement to brain volume measures to analyse possible parallel ongoing in vivo processes during the follow-up time. It was shown that brain volume loss continues throughout the 3-year followup period despite an effective anti-inflammatory treatment with natalizumab [7] , but the cohort size did not permit well-powered true multivariate modelling of this brain volume outcome. Parallel with this brain volume loss, 1 H MRS metabolites in NAWM were stable. Our results indicate that CSF levels of NFL and tau are associated with the extent of future brain volume loss in inflammatory active MS.
The total brain volume decrease over 3 years was 3%, as measured by the decline in PBVC. The loss was most evident (À1.7%) during the first year of treatment, and slightly more pronounced when excluding patients with relapses during follow-up. The latter finding suggests that a decline in PBVC may be alleviated by relapse-related oedema. The rate of brain volume loss in normal aging is estimated to be 0.1%-0.3% per year and in MS 0.5%-1.35% per year [2, 19] . There is only one previous report on natalizumab-treated MS patients followed for 3 years, showing a total mean decline in PBVC of 2.1% during the 3-year follow-up [20] . In addition, there are two reports on PBVC in natalizumab-treated MS where patients were followed for 18 months, showing a mean decrease in PBVC of À1.18% and À2.5%, respectively [21, 22] . Taken together, our data are well in line with earlier studies, although results are not identical. A main explanation for variations is probably patient heterogeneity since age, disease duration and baseline EDSS differed between studies. However, a consistent finding in all studies (including ours) was the pattern of an accentuated brain volume loss during the first year of treatment. This rapid initial brain volume change is considered to represent non-tissue related brain volume loss (pseudoatrophy), in particular resolution of oedema, although it may mask ongoing 'true' concurrent tissue-related brain volume loss (such as loss of myelin, axons and glial cells). The inflammatory oedema linked to pseudoatrophy is suggested to originate mainly from focal white matter lesions, whereas tissue-related brain volume loss is proposed to be a diffuse process affecting both white and grey matter [23] . In accordance with this view, no changes in 1 H MRS metabolite concentrations or in free water content (R 2 ) in NAWM at 1-year follow-up were found. This indicates that neither changed metabolite composition nor water content in NAWM could account for brain volume loss linked to pseudoatrophy. During the follow-up period of 3 years, the predominant non-tissue related brain volume loss during the first year of treatment is probably replaced by brain volume loss due to tissue-related damage, i.e. irreversible neuroaxonal damage. Since mean metabolite concentrations in NAWM were unchanged during the entire follow-up period, tissue-related brain volume loss in our cohort did not seem to take place in NAWM. Taken together, our data thus indicate that the observed decline in whole brain volume depends on processes affecting regions other than NAWM, like lesional white matter and grey matter. The view of lesional white matter being affected is supported by an autopsy study on global brain pathology showing that patients with relapsing MS (as in our present study) mainly presented new and active focal demyelinating lesions in white matter, whilst patients with progressive MS showed a diffuse inflammatory reaction in NAWM as well as cortical demyelination [24] .
Correlation analyses showed that a higher rate of brain volume loss was associated with increasing tNA concentrations in NAWM. The explanation for this observation may be that the viability of axons (reflected by tNA levels) increases with the resolution of oedema in adjacent or distant lesions. This is supported by the fact that concentrations of tNA may fluctuate over time and thus a decline in tNA levels could indicate a possible reversible axonal dysfunction rather than a permanent axonal loss [25] .
The potentially most useful finding in this study was the association between brain volume loss over 3 years and elevated levels of NFL and tau in CSF at baseline. Neurofilaments are major components of axonal cytoskeleton proteins. Inflammatory demyelination may cause disruption of axonal integrity and release of neurofilaments in the extracellular fluid. CSF levels of NFL, the smallest of three neurofilament chains, has thus been linked to inflammation and ongoing axonal damage [26] [27] [28] . Tau protein is primarily found in neuronal structures and promotes axonal stability and intraneuronal transport [29] . Combined analysis of neurofilaments and tau has been shown to predict conversion from clinically isolated syndrome to MS [30] . As with NFL, tau protein is considered to be released into CSF after axonal damage. However, in contrast to NFL [8, 27, 31] , data on tau in MS are inconsistent [32, 33] . In line with our previous reported findings in this cohort [8] , mean levels of NFL decreased (897-351 ng/l, P = 0.0002) whereas mean levels of tau were almost identical (44.2-44.3 ng/l, P = 0.049) after 1-year natalizumab treatment. At 1-year follow-up only one patient had increased NFL levels and six patients had increased tau levels, but none of these patients had a relapse during the first year of treatment. It is reported here that CSF levels of NFL and tau were associated with long-term brain volume loss. This finding implicates that these markers reflect the baseline level of intrathecal inflammation with axonal damage that within 3 years accounts for tissue-related brain volume loss, i.e. brain atrophy. In this perspective levels of NFL and tau are associated with axonal damage secondary to inflammation, suggesting that they may be used as markers for response of anti-inflammatory treatment.
To conclude, this 3-year longitudinal study of natalizumab-treated MS shows that, despite unchanged metabolite levels in NAWM, there is a continuous significant brain volume loss throughout the 3-year follow-up time. Furthermore, levels of NFL and tau in CSF were associated with the rate of brain volume loss indicating that NFL and tau may be used as markers for brain atrophy development and possibly also for evaluating anti-inflammatory treatment response in MS.
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